SCHEMBL3780245

SCHEMBL3780245

CC(=O)N1CCc2cc(B3OC(C)(C)C(C)(C)O3)ccc2C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.51
ROCK1 Q13464 1/20 0.50
ESR2 Q92731 5/20 0.39
ESR1 P03372 4/20 0.39
HRH3 Q9Y5N1 2/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
PRMT5 O14744 1/20 0.38
ABHD6 Q9BV23 2/20 0.37
BACE1 P56817 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
PAK1 Q13153 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4312462 0.95 NOTUM (0.51) NOTUMROCK1ESR2ESR1HRH3
SCHEMBL588250 0.90 ROCK1 (0.50) NOTUMROCK1ESR2ESR1HDAC8
SCHEMBL3776635 0.86 ROCK1 (0.53) NOTUMROCK1ESR2ESR1MEN1
SCHEMBL21198478 0.86 HDAC6 (0.55) NOTUMROCK1ESR2ESR1HDAC8
SCHEMBL21217859 0.86 ROCK1 (0.53) NOTUMROCK1ESR2ESR1HDAC8
SCHEMBL14677187 0.85 ESR2 (0.58) NOTUMROCK1ESR2ESR1HDAC8
SCHEMBL16492544 0.85 ROCK1 (0.47) NOTUMROCK1ESR2ESR1ABHD6
SCHEMBL29676899 0.83 ESR2 (0.62) ROCK1ESR2ESR1HDAC8HDAC6
SCHEMBL587184 0.83 ESR2 (0.62) ROCK1ESR2ESR1HDAC8HDAC6
SCHEMBL4555320 0.81 ROCK1 (0.54) ROCK1BACE1CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023008577-A1 RAS/RAF BINDING INHIBITOR COMPOUND 国立大学法人神戸大学 2023-02-02 WO disclosed
US-9169259-B2 Imidazopyridazine compounds HOFFMANN-LA ROCHE INC. (US) 2015-10-27 US disclosed
US-9169259-B2 Imidazopyridazine compounds HOFFMANN-LA ROCHE INC. (US) 2015-10-27 US disclosed
US-20130109661-A1 IMIDAZOPYRIDAZINE COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2013-05-02 US disclosed
US-20130109661-A1 IMIDAZOPYRIDAZINE COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2013-05-02 US disclosed
US-20100331312-A1 MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2010-12-30 US disclosed
EP-2265587-A1 MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2010-12-29 EP disclosed
WO-2009105206-A1 MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331312-A1 MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO HRH3, HRH4, HRH1 NOTUM 683/4885ROCK1 2496/4885ESR2 1760/4885
US-20130109661-A1 IMIDAZOPYRIDAZINE COMPOUNDS SYK, BTK, IRAK4 NOTUM 3369/4885ROCK1 1542/4885ESR2 2050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.